Journals / Akademik Gastroenteroloji Dergisi / 2024 / Cilt: 23 Sayı: 2

Has the treatment of chronic hepatitis C come to an end? Single center experience

Kronik hepatit C tedavisinde sona mı gelindi? Tek merkez deneyimi

Bulent Albayrak(Atatürk Üniversitesi, Tıp Fakültesi, Gastroenteroloji Bilim Dalı, Erzurum,)0000-0003-1231-152X
Harun Yetimoğlu(Atatürk Üniversitesi, Tıp Fakültesi, Gastroenteroloji Bilim Dalı, Erzurum)0009-0009-2478-3445
Murat Altunok(Atatürk Üniversitesi, Tıp Fakültesi, Nefroloji Bilim Dalı, Erzurum)0000-0001-6122-6829
Pages
49–53
Publication Date
2024-08-27
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result, eradication of chronic hepatitis C virus infection seems possible with second-generation drugs with high treatment success and low side effect profiles.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Aims: Direct-acting antiviral combinations have been shown to be highly effective in reducing the burden of chronic hepatitis C virus infection in clinical studies and are recommended by the European Association for the Study of the Liver treatment guidelines.
📊
Key Findings & Data:Materials and Methods: This study included 47 patients who were diagnosed with chronic hepatitis C virus infection and were given Glecaprevir/Pibrentasvir treatment for 8 weeks and completed the treatment at the gastroenterology clinic of Atatürk University Research Hospital.
💡
Conclusion & Impact:As a result, eradication of chronic hepatitis C virus infection seems possible with second-generation drugs with high treatment success and low side effect profiles.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Kronik hepatit C · güncel tedavi · kalıcı virolojik yanıt

Abstract

Background and Aims: Direct-acting antiviral combinations have been shown to be highly effective in reducing the burden of chronic hepatitis C virus infection in clinical studies and are recommended by the European Association for the Study of the Liver treatment guidelines. We aimed to present the results of the Glecaprevir/Pibrentasvir treatment regimen used in the current treatment of chronic hepatitis C virus infection, which is one of the most important health problems in our center. Materials and Methods: This study included 47 patients who were diagnosed with chronic hepatitis C virus infection and were given Glecaprevir/Pibrentasvir treatment for 8 weeks and completed the treatment at the gastroenterology clinic of Atatürk University Research Hospital. Demographic and laboratory data of the patients were evaluated based on age, gender, hepatitis C virus subtype, and HCV-RNA level. HCV-RNA levels at treatment initiation, week 12, and end of treatment were recorded for patients who completed treatment. The HCV-RNA level at week 12 post-treatment was used to assess sustained virologic response. Results: The mean age of 47 patients receiving Glecaprevir/Pibrentasvir treatment was 57.64 ± 15.71 years, 20 (42.62%) were female and 27 (57.4%) were male. The initial HCV-RNA level was determined as 6.65 ± 6.77 log IU/ml. HCV-RNA levels of the patients who came for follow-up at the end of treatment 12th week were measured as negative. No side effects that would cause discontinuation of treatment were observed in these patients. Conclusion: Real-life data on the Glecaprevir/Pibrentasvir treatment protocol in hepatitis C virus infection have been reported. As a result, eradication of chronic hepatitis C virus infection seems possible with second-generation drugs with high treatment success and low side effect profiles.

Özet

Giriş ve Amaç: Direkt etkili antiviral kombinasyonlarının, klinik çalışmalarda kronik hepatit C virüsü enfeksiyon yükünü azaltmada oldukça etkili olduğu gösterilmiştir ve Avrupa Karaciğer Çalışmaları Derneği tedavi kılavuzları tarafından da tavsiye edilmektedir. Merkezimizde en önemli sağlık sorunlarından biri olan kronik hepatit C virüsü enfeksiyonunda güncel tedavide kullanılan Glecaprevir/Pibrentasvir tedavi rejiminin sonuçlarını sunmayı amaçladık. Gereç ve Yöntem: Bu çalışmaya, Atatürk Üniversitesi Araştırma Hastanesi Gastroenteroloji Kliniğinde tedavi naif kronik hepatit C enfeksiyonu tanısı ile 8 hafta Glecaprevir/Pibrentasvir tedavisi verilen ve tedaviyi tamamlayan 47 hasta dahil edildi. Hastaların yaş, cinsiyet, hepatit C virüsü genotip alt tipi, HCV-RNA düzeyi temelinde demografik ve laboratuvar verileri değerlendirildi. Tedaviyi tamamlayan hastaların tedavi başlangıç, 12. hafta, tedavi sonu HCV-RNA düzeyleri kaydedildi. Tedavi sonrası 12. hafta HCV-RNA düzeyi kalıcı viral yanıt değerlendirilmesinde kullanıldı. Bulgular: Glecaprevir/Pibrentasvir tedavisi alan 47 hastanın yaş ortalaması 57.64 ± 15.71 olup, 20’si (%42.62) kadın 27’si(%57.4) erkek idi. Başlangıç HCV-RNA düzeyi 6.65 ± 6.77 log IU/ml olarak saptandı. Tedavi bitimini takiben 12. haftada kontrole gelen tüm hastaların HCV-RNA düzeyleri negatif olarak ölçüldü. Bu hastalarda tedaviyi kesmeyi gerektirecek herhangi bir yan etki gözlenmedi Sonuç: Hepatit C virüsü enfeksiyonunda Glecaprevir/Pibrentasvir tedavi sonuçlarına ilişkin Türkiye’den bir merkezin gerçek yaşam verileri bildirilmiştir. Sonuç olarak, yüksek tedavi başarısı ve düşük yan etki profiline sahip ikinci kuşak ilaçlar ile kronik hepatit C virüsü enfeksiyonunda eradikasyon mümkün gözükmektedir.

🔖

Cite This Article

Albayrak, B., Yetimoğlu, H., Altunok, M. (2024). Has the treatment of chronic hepatitis C come to an end? Single center experience. Akademik Gastroenteroloji Dergisi, Cilt: 23 Sayı: 2, 49–53. https://doi.org/10.17941/agd.1538498

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Martinello M, Solomon SS, Terrault NA, Dore GJ. Hepatitis C. Lancet. 2023;402(10407):1085-96.
  2. European Association for the Study of the Liver. Electronic address: [email protected]; Clinical Practice Guidelines Panel: Chair:; EASL Governing Board representative:; Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series☆. J Hepatol. 2020;73(5):1170-218.
  3. Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012;12(Suppl. 2):S2
  4. Huff J, Andersen R. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older. Ann Pharmacother. 2020;54(3):262-76.
  5. González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016;22(4):1421-32.
  6. Schneider MD, Kronenberger B, Zeuzem S, Sarrazin C. Treatment of hepatitis C. Internist (Berl). 2015;56(4):391-405.
  7. Aygen B, Keten D, Akalın H, et al. Kronik Hepatit C Virusu İnfeksiyonunun Yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu Uzlaşı Raporu. Klimik Dergisi 2014;27(Özel Sayı 1):19-39.
  8. Çetin Duran A, Kaya Çetinkaya Ö, Sayıner AA, et al. Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data. Turk J Gastroenterol. 2020;31(2):128-35.
  9. Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53.
  10. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-76.
  11. Hollande C, Parlati L, Pol S. Micro-elimination of hepatitis C virus. Liver Int. 2020;40(Suppl 1):67-71.
  12. Rabaan AA, Al-Ahmed SH, Bazzi AM, et al. Overview of hepatitis C infection, molecular biology, and new treatment. J Infect Public Health. 2020;13(5):773-83.
  13. Applegate TL, Fajardo E, Sacks JA. Hepatitis C Virus Diagnosis and the Holy Grail. Infect Dis Clin North Am. 2018;32(2):425-45.
  14. Krarup H. [Diagnostics of hepatitis C] [Article in Danish]. Ugeskr Laeger. 2021;183(46): V05210420.